[HTML][HTML] PI3K/Akt/mTOR pathway and its role in cancer therapeutics: are we making headway?

Y Peng, Y Wang, C Zhou, W Mei, C Zeng - Frontiers in oncology, 2022 - frontiersin.org
Cancer is a severe public health issue that is a leading cause of mortality globally. It is also
an impediment to improving life expectancy worldwide. Furthermore, the global burden of …

Dynamic EMT: a multi‐tool for tumor progression

S Brabletz, H Schuhwerk, T Brabletz… - The EMBO journal, 2021 - embopress.org
The process of epithelial–mesenchymal transition (EMT) is fundamental for embryonic
morphogenesis. Cells undergoing it lose epithelial characteristics and integrity, acquire …

[HTML][HTML] Exosomes: key players in cancer and potential therapeutic strategy

J Dai, Y Su, S Zhong, L Cong, B Liu, J Yang… - Signal transduction and …, 2020 - nature.com
Exosomes are extracellular vesicles secreted by most eukaryotic cells and participate in
intercellular communication. The components of exosomes, including proteins, DNA, mRNA …

[HTML][HTML] EMT, cancer stem cells and autophagy; The three main axes of metastasis

G Babaei, SGG Aziz, NZZ Jaghi - Biomedicine & Pharmacotherapy, 2021 - Elsevier
Epithelial-mesenchymal transition (EMT) and Cancer stem-like cells (CSCs) are major
factors contributing to the metastasis of cancer cells. Consequently, the signaling pathways …

[HTML][HTML] Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies

ZD Shi, K Pang, ZX Wu, Y Dong, L Hao… - … and Targeted Therapy, 2023 - nature.com
Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

Novel therapeutic strategies: Targeting epithelial–mesenchymal transition in colorectal cancer

N Zhang, AS Ng, S Cai, Q Li, L Yang, D Kerr - The lancet oncology, 2021 - thelancet.com
Epithelial–mesenchymal transition (EMT) is a process during which cells lose their epithelial
characteristics, for instance apical–basal cell polarity and cell–cell contact, and gain …

[HTML][HTML] Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments

X Wei, Y Chen, X Jiang, M Peng, Y Liu, Y Mo, D Ren… - Molecular cancer, 2021 - Springer
Background Vasculogenic mimicry (VM) is a recently discovered angiogenetic process
found in many malignant tumors, and is different from the traditional angiogenetic process …

Managing metastatic melanoma in 2022: a clinical review

B Switzer, I Puzanov, JJ Skitzki, L Hamad… - JCO oncology …, 2022 - ascopubs.org
Cutaneous melanoma remains the most lethal of the primary cutaneous neoplasms, and
although the incidence of primary melanoma continues to rise, the mortality from metastatic …

[HTML][HTML] Targeting TGFβ signal transduction for cancer therapy

S Liu, J Ren, P Ten Dijke - Signal transduction and targeted therapy, 2021 - nature.com
Transforming growth factor-β (TGFβ) family members are structurally and functionally related
cytokines that have diverse effects on the regulation of cell fate during embryonic …

[HTML][HTML] ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance

J Fan, KKW To, ZS Chen, L Fu - Drug Resistance Updates, 2023 - Elsevier
Multidrug resistance (MDR) is the phenomenon in which cancer cells simultaneously
develop resistance to a broad spectrum of structurally and mechanistically unrelated drugs …